-3- 
the possibility of the Committee reviewing genetic research in 
general; and, the immediate approach to be taken by the regulatory 
agencies in determining the authority of each agency in the regulation 
of recombinant DNA research. 
Dr. Fredrickson then brought the meeting to a close by 
requesting 
• the performer agencies to submit a written statement 
analyzing the nature and extent of actual or planned 
recombinant DNA research and the role of the agency 
vis-a-vis the eleven functions/processes previously 
ment loned 
• the regulatory agencies to submit a written statement 
analyzing the authority and role of the agency in the 
regulation of recombinant DNA research 
and by announcing his intention to reconvene the Committee within 
three weeks. The agenda for this meeting will consist of a discussion 
of the two items above plus any other topics suggested by the agency 
representatives. Dr. Fredrickson received Committee approval to 
create a subcommittee for the purpose of developing future agendas 
and Issues for review. 
Respectfully submitted, 
Associate Director for 
Program Planning and Evaluation 
National Institutes of Health 
Bethesda, Maryland 20014 
November 9, 1976 
[ 167 ] 
